The artificial intelligence (AI)-based technology reportedly facilitates optimal contrast-to-noise ratios with medical imaging.
Separating noise from an image without affecting the quality of the image has been a longtime challenge for radiologists. However, an emerging technology may provide a solution to this dilemma.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the dose reduction capabilities of Carestream Health’s Smart Noise Cancellation (SNC) technology, according to the manufacturer.
Traditional noise reduction for medical imaging can lead to blurring that may obscure key anatomical detail and reduce the sharpness of the image. Carestream Health said the artificial intelligence (AI)-based SNC technology enables radiologists to ensure optimal contrast-to-noise ratios while preserving image quality and anatomical detail.
“Our AI-powered Smart Noise Cancellation gives radiologists another important tool to adjust the amount of noise cancellation and exposure to meet the desired imaging quality to aid their diagnosis,” noted Ron Muscosky, a worldwide product line manager at Carestream Health.
The SNC technology is currently available on the Carestream Health’s DRX-Evolution and DRX-Evolution Plus systems. The company added that the combination of SNC technology with Carestream Health’s SmartGrid software may enhance grid-less imaging. The SNC technology may be particularly beneficial for imaging in younger populations, according to Muscosky.
“This improved capability to optimize radiation dose will be especially valuable in neonatal and pediatric diagnostic imaging where imaging at the lowest possible dose is crucial for young patients,” said Muscosky.
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.